Rehmaglutin D is primarily investigated for its potential antidiabetic properties, particularly in the management of type 2 diabetes. It functions by enhancing glucose-dependent insulin secretion, thereby helping to regulate blood glucose levels more effectively. The compound also shows promise in improving insulin sensitivity and protecting pancreatic beta cells from glucotoxicity and oxidative stress. Due to these effects, Rehmaglutin D is being explored as a candidate for developing new oral hypoglycemic agents. Additionally, it may contribute to reducing diabetic complications by modulating key signaling pathways involved in inflammation and metabolic regulation. Research is ongoing to evaluate its long-term efficacy and safety profile in preclinical and clinical settings.